Teresa Klepacka

Teresa Klepacka

Auto-generated profile, based on publicly available information

Teresa Klepacka

Department of Pathology, Institute of Mother and Child, Kasprzaka 17a, 01-211 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JRJoanna Radzikowska
Joanna Radzikowska
AKAntoni Krzeski
Antoni Krzeski
Anna M. Czarnecka, MBAAnna M. Czarnecka, MBA
Anna M. Czarnecka, MBA
TKTeresa Klepacka
Teresa Klepacka
MRMagdalena Rychlowska-Pruszynska
Magdalena Rychlowska-Pruszynska
WKWojciech Kukwa
Wojciech Kukwa
(1) Background: The study proposed to analyze microvessel density (MVD) in rhabdomyosarcoma (RMS) based on the expression of angiogenesis markers and define its prognostic role in this group of patients. (2) Methods: The study included forty-nine pediatric patients diagnosed with RMS. Tumor tissue expression of CD31, CD34, and CD105 was analyzed. MVD was calculated and correlated with clinical RMS prognostic parameters. (3) Results: CD31, CD34, and CD105 are expressed in all RMS cases. MVD/CD105 was significantly higher in the RMS group than in the control group. The mean and median values of MVD/CD105 in RMS were lower than MVD/CD31 and MVD/CD34. MVD/CD105 was significantly higher in patients with alveolar RMS and those with metastatic disease. Patients with higher levels of MVD/CD105 had a higher risk of death (HR = 1.009). (4) Conclusion: CD105 is a relevant angiogenesis marker in pediatric RMS, and MVD/CD105 is an independent risk factor of short overall survival in children with RMS.

4 August 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
JRJoanna Radzikowska
Joanna Radzikowska
Anna M. Czarnecka, MBAAnna M. Czarnecka, MBA
Anna M. Czarnecka, MBA
TKTeresa Klepacka
Teresa Klepacka
MRMagdalena Rychłowska-Pruszyńska
Magdalena Rychłowska-Pruszyńska
ARAnna Raciborska
Anna Raciborska
AKAntoni Krzeski
Antoni Krzeski
(1) Background: The aim of the present study was to assess the cancer stem cell (CSC) markers CD24, CD44, CD133, and ALDH1A1 in rhabdomyosarcoma (RMS) in children and to define their prognostic role in this group of patients. (2) Methods: The study material was archival tissue specimens collected from 49 patients under 18 years of age and who had been diagnosed with RMS. Immunohistochemistry (IHC) was used to evaluate the expression of the selected CSC markers in the tumor tissue. Expression was evaluated using a semiquantitative IRS scale based on the one developed by Remmele and Stenger and was correlated with the clinical and pathomorphological parameters of prognostic importance in RMS. (3) Results: Expression of the selected CSC markers CD24, CD44, CD133, and ALDH1A1 was demonstrated in 83.7%, 55.1%, 81.6%, and 100% of the RMS patients, respectively. The expression of all of the assessed CSC markers was statistically significantly higher in the study group versus the control group. No significant correlation was found between the expression of the selected CSC markers and clinical and pathological prognostic factors that were analyzed. The expression of the CSC markers did not have a significant influence on RMS survival rates. (4) Conclusions: The results of the conducted study confirm the expression of selected CSC markers in rhabdomyosarcoma tissue in children. The study did not support the prognostic relevance of the expression of any of the assessed CSC markers. However, further studies are needed to fully understand the relevance of the selected CSC markers in RMS carcinogenesis.